May P R, Van Putten T
Arch Gen Psychiatry. 1978 Sep;35(9):1081-7. doi: 10.1001/archpsyc.1978.01770330055004.
Measurment of chloropromazine and metabolite levels in the blood has not yet developed such that it can help the clinician. Apart from their chemistry, the clinical aspects of the experimentql design of most studies leave much to be desired, so that it is not possible to draw any overall conclusions about the relationship between chlorpromazine blood levels and clinical outcome from the data currently available. Measurement of response to a single test dose may prove potentially more fruitful in predicting outcome and in establishing drug and dosage choice for a given patient than simple attempts to correlate sustained dosage levels with clinical response. For chlorpromazine, indeed for any drug, it would seem wise in the first instance to focus clinically well-designed studies on the parent substance, rather than launching into more costly, but clinically unsophisticated, studies of its metabolites.
血液中氯丙嗪及其代谢物水平的测量方法尚未发展到能帮助临床医生的程度。除了其化学性质外，大多数研究的实验设计在临床方面还有很多不足之处，因此无法从目前可得的数据中就氯丙嗪血药浓度与临床结果之间的关系得出任何总体结论。与简单地试图将持续剂量水平与临床反应相关联相比，测量对单次试验剂量的反应可能在预测结果以及为特定患者确定药物和剂量选择方面更有成效。对于氯丙嗪，实际上对于任何药物来说，首先将临床设计良好的研究重点放在母体物质上似乎是明智的，而不是开展成本更高但临床方面不够精细的其代谢物研究。
